Guidelines, “minimal requirements” and standard of care in glioblastoma around the Mediterranean Area: A report from the AROME (Association of Radiotherapy and Oncology of the Mediterranean arEa) Neuro-Oncology working party

Belkacémi, Yazid; Bolle, Stéphanie; Bourdeaut, Franck; Cornu, Philippe; Delatre, J.-Y.; Dhermain, F.; Doz, François; Habrand, Jean Louis; Hoang-Xuân, Khê; Idbaïh, Ahmed; Mammar, Hamid; Martin-Duverneuil, N; Mokhtari, Karima; Roujeau, Thomas; Acharqui, A.; Benali, S. Atit; Bakhti, Sepideh; Bena, F.; Bendjaafar, N.; Benider, A.; Bouaouina, N; Bounedjar, A.; Boussen, Hamouda; Bouyoucef, K.; Bouzid, K.; Chougai, Z.; Daoud, J.; Errihani, Hassan; Essoudaigui, F.; Gachi, F.; Hilmani, S.; Hsissen, L.; Idali, B.; Karkouri, Mehdi; Kerboua, Esma; Ouahabi, Abdessamad El; Sahraoui, S.; Harif, Mhamed; Sadki, O.; Sami, Abdus; Samlali, R; Terkmani, F.

doi:10.1016/j.critrevonc.2015.10.014

Cited by 4 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is an aggressive astrocytic tumor (grade IV in the WHO designation) associated with a median overall survival of 12 months after standard therapy and a relative survival of 8.8% at three years and only 5.1% at five years (6.3% in Europe) [ 1 , 2 ]. The standard treatment of GBM consists of surgery associated with radiotherapy and chemotherapy with temozolomide, a prodrug of a cytotoxic agent able to alkylate DNA [ 3 ]. However, there are no guidelines for the treatment of relapses.…”

Section: Introductionmentioning

confidence: 99%

Co-Encapsulation of Fisetin and Cisplatin into Liposomes for Glioma Therapy: From Formulation to Cell Evaluation

et al. 2021

View full text Add to dashboard Cite

(1) Background: Glioblastoma (GBM) is the most frequent cerebral tumor. It almost always relapses and there is no validated treatment for second-line GBM. We proposed the coencapsulation of fisetin and cisplatin into liposomes, aiming to (i) obtain a synergistic effect by combining the anti-angiogenic effect of fisetin with the cytotoxic effect of cisplatin, and (ii) administrate fisetin, highly insoluble in water. The design of a liposomal formulation able to encapsulate, retain and deliver both drugs appeared a challenge. (2) Methods: Liposomes with increasing ratios of cholesterol/DOPC were prepared and characterized in term of size, PDI and stability. The incorporation of fisetin was explored using DSC. The antiangiogneic and cytotoxic activities of the selected formulation were assayed in vitro. (3) Results: We successfully developed an optimized liposomal formulation incorporating both drugs, composed by DOPC/cholesterol/DODA-GLY-PEG2000 at a molar ratio of 75.3/20.8/3.9, with a diameter of 173 ± 8 nm (PDI = 0.12 ± 0.01) and a fisetin and cisplatin drug loading of 1.7 ± 0.3% and 0.8 ± 0.1%, respectively, with a relative stability over time. The maximum incorporation of fisetin into the bilayer was determined at 3.2% w/w. Then, the antiangiogenic activity of fisetin was maintained after encapsulation. The formulation showed an additive effect of cisplatin and fisetin on GBM cells; (4) Conclusions: The developed co-loaded formulation was able to retain the activity of fisetin, was effective against GBM cells and is promising for further in vivo experimentations.

show abstract

Section: Introductionmentioning

confidence: 99%

Co-Encapsulation of Fisetin and Cisplatin into Liposomes for Glioma Therapy: From Formulation to Cell Evaluation

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Three-dimensional conformal radiotherapy and its derivates, Intensity Modulated Radiation Therapy (IMRT) and Volumetric Arc Therapy (VMAT) are now standard of treatment for patients with glioblastoma. 5 , 6 , 7 Standard postoperative treatment of patients with glioblastoma consist of postoperative radiotherapy with temozolomide followed by adjuvant temozolomide. 8 , 9 , 10 , 11 Radiotherapy is corner-stone of multimodality approach and it is considered as treatment with highest benefit of all three treatment modalities.…”

Section: Introductionmentioning

confidence: 99%

Impact on radiation dose and volume V57 Gy of the brain on recurrence and survival of patients with glioblastoma multiformae

Stojkovski

Krstevska

Smichkoska

2017

Radiology and Oncology

View full text Add to dashboard Cite

BackgroundThe aim of the study was to analyze impact of irradiated brain volume V57 Gy (volume receiving 57 Gy and more) on time to progression and survival of patients with glioblastoma.Patients and methodsDosimetric analysis of treatment plan data has been performed on 70 patients with glioblastoma, treated with postoperative radiochemotherapy with temozolomide, followed by adjuvant temozolomide. Patients were treated with 2 different methods of definition of treatment volumes and prescription of radiation dose. First group of patients has been treated with one treatment volume receiving 60 Gy in 2 Gy daily fraction (31 patients) and second group of the patients has been treated with “cone-down” technique, which consisted of two phases of treatment: the first phase of 46 Gy in 2 Gy fraction followed by “cone-down” boost of 14 Gy in 2 Gy fraction (39 patients). Quantification of V57 Gy and ratio brain volume/V57Gy has been done. Average values of both parameters have been taken as a threshold value and patients have been split into 2 groups for each parameter (values smaller/ lager than threshold value).ResultsMean value for V57 Gy was 593.39 cm3 (range 166.94 to 968.60 cm3), mean value of brain volume has was 1332.86 cm3 (range 1047.00 to 1671.90 cm3) and mean value of brain-to-V57Gy ratio was 2.46 (range 1.42 to 7.67). There was no significant difference between two groups for both V57 Gy and ratio between brain volume and V57 Gy.ConclusionsIrradiated volume with dose 57 Gy or more (V57 Gy) and ration between whole brain volume and 57 Gy had no impact on time to progression and survival of patients with glioblastoma.

show abstract

Glioblastoma: State of the Art of Treatments and Applications of Polymeric and Lipidic Nanomedicines

et al. 2020

View full text Add to dashboard Cite

Guidelines, “minimal requirements” and standard of care in glioblastoma around the Mediterranean Area: A report from the AROME (Association of Radiotherapy and Oncology of the Mediterranean arEa) Neuro-Oncology working party

Cited by 4 publications

References 37 publications

Co-Encapsulation of Fisetin and Cisplatin into Liposomes for Glioma Therapy: From Formulation to Cell Evaluation

Co-Encapsulation of Fisetin and Cisplatin into Liposomes for Glioma Therapy: From Formulation to Cell Evaluation

Impact on radiation dose and volume V57 Gy of the brain on recurrence and survival of patients with glioblastoma multiformae

Glioblastoma: State of the Art of Treatments and Applications of Polymeric and Lipidic Nanomedicines

Contact Info

Product

Resources

About